Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug use of 5-bromo-2-(alpha-hydroxypentyl) sodium benzoate in treatment of cardiac hypertrophy and heart failure

A technology of sodium benzoate and hydroxypentyl, which is applied in the field of biomedicine and can solve problems not involved in the application of BZP

Inactive Publication Date: 2019-01-18
ZHENGZHOU UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its specification discloses that sodium salt of 5-bromo-2-(a-hydroxypentyl)benzoate can significantly reduce brain tissue damage caused by cerebral artery occlusion in rats, reduce cerebral infarction volume, and reduce brain edema volume, but it does not involve BZP Application in the treatment of pressure overload-induced cardiac hypertrophy and heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug use of 5-bromo-2-(alpha-hydroxypentyl) sodium benzoate in treatment of cardiac hypertrophy and heart failure
  • Drug use of 5-bromo-2-(alpha-hydroxypentyl) sodium benzoate in treatment of cardiac hypertrophy and heart failure
  • Drug use of 5-bromo-2-(alpha-hydroxypentyl) sodium benzoate in treatment of cardiac hypertrophy and heart failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0020] Example: Protective Effect of BZP on C57BL / 6 Mice Pressure Load-Induced Cardiac Hypertrophy and Heart Failure Experimental Materials and Methods

[0021] (1) Experimental materials

[0022] 8-week-old C57BL / 6 mice, weighing 19-22 g, all male, BZP (5-bromo-2-(α-hydroxypentyl) benzoic acid sodium salt) powder, prepared with double distilled water.

[0023] (2) Experimental grouping

[0024] Randomly divided into 4 groups, respectively: sham operation group (Sham); myocardial hypertrophy model group (TAC); BZP (5-bromo-2-(α-hydroxypentyl) benzoic acid sodium salt) high-dose group (40mg / kg ), BZP (5-bromo-2-(α-hydroxypentyl) benzoic acid sodium salt) low dose group (20mg / kg).

[0025] (3) Long-term administration method

[0026] Treatment group: BZP (5-bromo-2-(α-hydroxypentyl)benzoic acid sodium salt) was given by intragastric administration after the TAC model was established, the doses were 20 mg / kg and 40 mg / kg respectively. The dosing volume was 0.01 ml / g.

[0027...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine and discloses drug use of 5-bromo-2-(alpha-hydroxypentyl) sodium benzoate (BZP) in treatment of cardiac hypertrophy and heart failure. Mice with myocardial hypertrophy induced by pressure overload after aortic coarctation were used in this study. The effects of pressure overload on myocardial hypertrophy, It was found that oral administration of BZP could decrease the cardiac weight-to-body weight ratio after aortic coarctation in mice, Heart weight tibia length ratio, reduce the cross-sectional area of hypertrophic cardiomyocytes, reduce the level of myocardial fibrosis, reduce the expression of hypertrophy-related genes, improve cardiac function injury induced by pressure load, reduce myocardial hypertrophy, reduce the occurrence of myocardial remodeling, and postpone the process of heart failure. It will hopefully be developed into a new class of drugs for cardiovascular treatment.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the medicinal use of 5-bromo-2-(α-hydroxypentyl)benzoic acid sodium salt (BZP) in treating pressure load-induced myocardial hypertrophy and heart failure. Background technique [0002] Cardiac hypertrophy is an adaptive response of cardiomyocytes to various pathological stimuli such as mechanical load and neurohumoral stimulation. In the early stage, it is regarded as a compensatory process due to the thickening of the ventricular wall and the improvement of myocardial systolic function, but in the case of persistent pathological stress, accompanied by interstitial fibrosis, systolic dysfunction, and cardiac chamber enlargement, it will eventually lead to dysfunction. Compensated heart failure and even sudden death. Up to now, cardiac hypertrophy has been considered as an independent risk factor for adverse cardiovascular events. The prevention and timely treatment of myocardial hypert...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61P9/00A61P9/04
CPCA61K31/192A61P9/00A61P9/04
Inventor 常俊标张金盈赵文宋传君王勃
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com